On April 30, 2026, Cadrenal Therapeutics announced that the FDA had cleared a path to a pivotal Phase 3 trial for CAD-1005 in heparin-induced thrombocytopenia (HIT). The Phase 2 study showed a more than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy. If CAD-1005 is approved, it would be the first new drug specifically developed for HIT since argatroban in 2000 (Cadrenal Therapeutics, 2026).
HIT is rare, but the patients who develop it are usually critically ill and already in the hospital. It is a paradox: a complication of the most widely used blood thinner in the world that turns the body's own platelets into clot factories. Mortality has been reported above 20% in some studies. The standard treatment options work by managing the clotting downstream rather than by stopping the underlying immune mechanism. CAD-1005 takes a different approach.
What HIT Actually Does
Heparin is given to roughly 12 million hospitalized patients in the United States each year (Cadrenal Therapeutics, 2026). For most, it does what it's supposed to: thin the blood, prevent clots, support recovery from surgery or critical illness. For a small percentage, the body forms an immune response against the heparin/platelet factor 4 (PF4) complex. Those antibodies bind to platelets and switch them on. Two things follow at the same time. The platelet count drops (thrombocytopenia). Massive new clots form throughout the circulatory system (thrombosis).
The combination is dangerous in a way that catches clinicians off guard. Most low-platelet syndromes cause bleeding. HIT causes clotting, even though the platelet count is dropping. Without quick recognition and a switch to a non-heparin anticoagulant, patients can develop deep vein thrombosis, pulmonary embolism, stroke, heart attack, or limb ischemia. Some need amputation. Some don't survive (American Society of Hematology, 2018).
Why HIT Hasn't Had a New Drug in 25 Years
The current treatment playbook for HIT was built around a single insight: stop heparin, switch to a non-heparin anticoagulant, prevent additional clots while the immune reaction settles. The drugs used to do that are direct thrombin inhibitors and a Factor Xa inhibitor. Lepirudin was the first FDA-approved option in 1998, but it was withdrawn from the global market in 2012. Argatroban was approved for HIT in 2000 (StatPearls, 2024). Bivalirudin and fondaparinux are widely used off-label, with bivalirudin formally approved only for use during percutaneous coronary intervention (Seybert et al., Pharmacotherapy 2006).
Each of these drugs prevents new clots. None of them quiets the immune-mediated platelet activation that drives HIT in the first place. Patients still face thrombotic events while on optimal therapy. Monitoring is complicated. Reversal agents are limited. Bleeding risk is real. After argatroban's approval in 2000, the drug development pipeline for HIT effectively stalled for 25 years.
How CAD-1005 Is Different
CAD-1005 is a first-in-class small-molecule inhibitor of 12-lipoxygenase, an enzyme inside platelets that the immune-mediated HIT process uses to keep activating more platelets. The cycle of HIT looks like this: heparin/PF4 antibodies bind platelets, the platelets activate, activation produces signals that pull in more platelets, more platelets activate, clots form. 12-LOX is one of the enzymes that helps drive that amplification. By blocking 12-LOX, CAD-1005 is designed to break the cycle inside the platelet, before downstream clotting takes over.
The mechanism is different from every existing HIT therapy. Argatroban, bivalirudin, and fondaparinux all act in the bloodstream, downstream of the platelet, to slow thrombin or Factor Xa. CAD-1005 targets the platelet itself.
The drug originated at Eastern Virginia Medical School (now part of Old Dominion University), was licensed to a biotech named Veralox Therapeutics under the development code VLX-1005, and then was acquired by Cadrenal Therapeutics in December 2025 along with the CAD-2000 series of follow-on oral 12-LOX inhibitors. CAD-1005 currently holds Orphan Drug Designation and Fast Track designation from the FDA, plus orphan drug status from the European Medicines Agency for platelet-activating factor 4 disorders (Cadrenal Therapeutics 10-K, 2026).
What the Phase 2 and EOP2 Meeting Showed
Phase 2 was a blinded, placebo-controlled study of 24 patients. Patients received CAD-1005 or placebo on top of the local standard of care for HIT. Cadrenal reported that the addition of CAD-1005 produced a more than 25% absolute reduction in new or worsening thrombotic events compared with placebo. The Phase 1 program had already exposed more than 100 patients to the compound, building the safety database the FDA used to evaluate the Phase 3 plan.
Cadrenal completed the End-of-Phase 2 (EOP2) meeting with the FDA on March 26, 2026. The agency provided guidance on protocol design, the study population, dosing, background therapy, the safety database, and the primary endpoint of new or worsening thrombotic events. After incorporating that guidance, Cadrenal disclosed the planned Phase 3 design publicly on April 30, 2026 (Cadrenal Therapeutics 10-K, 2026; Cadrenal Therapeutics, April 30, 2026).
The Phase 3 trial will be randomized, blinded, and placebo-controlled. Patients with suspected HIT will receive CAD-1005 or placebo on top of standard anticoagulant therapy and will be treated for up to 14 days during hospitalization. The primary endpoint, centrally adjudicated, is the incidence of new or worsening thrombotic events in patients with Serotonin Release Assay (SRA)-confirmed HIT. At least one interim analysis is planned. The protocol remains subject to additional FDA feedback as the agency reviews the final document.
“Interrupting the vicious cycle of platelet activation in HIT with CAD-1005 could be an important addition to our therapeutic armamentarium for this devastating condition.”
James J. Ferguson III, M.D., Chief Medical Officer, Cadrenal Therapeutics
What Patients and Families Should Watch
CAD-1005 is investigational. It is not yet available outside of clinical trials, and Phase 3 enrollment hasn't begun. Cadrenal's projected NDA submission is 2029, meaning the earliest possible FDA approval is several years out. Until then, the standard of care for HIT remains the same: stop all heparin products, switch to argatroban, bivalirudin, or fondaparinux, and consult a hematologist with thrombosis expertise.
If you or a family member has experienced HIT, a few things worth knowing today:
First, document everything. HIT antibodies can persist for weeks. Future heparin exposure can trigger a faster, more severe reaction. A medical alert bracelet, a clear allergy entry in every electronic health record, and a list of safer anticoagulants you tolerated are practical, low-cost protections.
Second, ask your hematologist about the Phase 3 trial when enrollment opens. The plan is to enroll across up to 50 sites worldwide, mostly at academic medical centers and large community hospitals. Site-specific listings will appear on ClinicalTrials.gov as the program activates. Trial Friend's HIT page refreshes those listings automatically.
Third, watch for a peer-reviewed publication of the Phase 2 data. The April 30, 2026 announcement was a corporate disclosure, not a journal manuscript. Detailed safety data, patient demographics, and the full effect size will land later in a hematology or anticoagulation journal.
Why This Matters Beyond CAD-1005
HIT is a small market by pharma standards. Roughly 1 in 50 to 1 in 200 hospitalized heparin patients develops HIT, depending on the type of heparin and the clinical setting (American Society of Hematology, 2018). For 25 years, that small market plus the difficulty of running placebo-controlled trials in a deadly, fast-moving condition was enough to keep HIT-specific drug development quiet.
An FDA-aligned Phase 3 path doesn't guarantee anything. Phase 3 trials in critically ill, hospitalized patients are hard to run. Enrollment can be slow because patients deteriorate quickly and informed consent is complicated. Safety signals that didn't appear in 24-patient Phase 2 can show up in 120-patient Phase 3. The drug may not show separation from placebo when the standard-of-care anticoagulants are already aggressive. None of those outcomes would be unusual.
The bigger picture is that 12-LOX inhibition as a therapeutic class now has a regulatory pathway that the FDA has agreed to. Second-generation oral 12-LOX compounds are in earlier development for chronic indications, including obesity-related inflammation and type 2 diabetes (Cadrenal Therapeutics, March 12, 2026). Whether or not CAD-1005 reaches approval, the work has opened a new mechanistic door.
For HIT patients, the next milestone to watch is Phase 3 trial activation on ClinicalTrials.gov. For the broader rare disease community, the next milestone is whether a single small biotech can run a 50-site, 120-patient pivotal trial in critically ill hospitalized patients without the operational and financial scale that bigger sponsors typically bring to programs of this complexity. The 25-year drought ends if both of those go well.